About

Built by an operator. Source-backed. Compliance-safe.

Clinical Trial Signal exists because the public-record intelligence on clinical trials, drug safety, and biotech disclosures is fragmented across a dozen agencies and feeds — and the firms that consolidate it charge $10K–$50K/yr for what is, structurally, public data.

Who

Founder

Thomas P. Gordon, JD

Phase3AI founder. Builds public-data intelligence products across regulated and adjacent industries — materials (ElementWatch), trade (TariffSignals), political narrative (CampaignBrief), freight (FreighterDeck), and now clinical trials and drug safety.

Parent

Phase3AI

A small, independent product studio that builds operator intelligence products on public-source backbones. Phase3AI products share one DNA: source-anchored, caveat-honest, compliance-safe, no surveillance-vendor pricing.

Lineage

Pattern, refined

ElementWatch monitors 27 critical materials. TariffSignals monitors 20 tariff domains. FreighterDeck monitors 12 freight domains. Clinical Trial Signal monitors clinical-trial registries, FDA, FAERS, DailyMed, PubMed, and EDGAR. Same architecture. Same operator-grade output.

Why now

Public data is high-quality. The interfaces around it are not.

ClinicalTrials.gov gives us free full study records. openFDA gives us free, structured access to FAERS, drug enforcement, and labels. SEC EDGAR exposes 8-K disclosures and 10-Q risk-factor language. PubMed gives us literature mentions on demand. DailyMed gives us current SPL label text.

Yet the standard answer for "track this drug" or "watch this sponsor" is to buy a $25,000/yr enterprise subscription to a legacy platform — or to manually monitor a dozen feeds and hope nothing breaks. We think there's a middle.

Clinical Trial Signal is that middle: source-backed, evidence-linked, AI-assisted briefs at consultant/analyst prices ($199–$699/mo), with a public methodology that anyone can audit.

Operating principles

Source-anchored

Every claim links to a primary public record. We never paraphrase official agency language away from its primary form.

Caveat-honest

FAERS reports cannot establish causation. Registry status doesn't reveal cause. We say so on every relevant card.

Compliance-safe

We are not a pharmacovigilance system, not a medical or legal advisor, not a regulatory determiner. Research screening only.

Operator-priced

$199 Pro · $399 Analyst Desk · $699 Enterprise. No enterprise sales cycle, no procurement ceremony. Cancel any time.

Audit-trail by default

Source, source URL, source timestamp, ingestion timestamp, raw record, normalized output. Enterprise-tier exports include the lot.

Methodology published

Severity labels, classification rules, what we infer and what we explicitly don't — all on /methodology. If you find a signal misclassified, tell us and we'll re-grade it.

Contact

Direct: tom@phase3ai.com
Press / partnerships: same address.
Security disclosure: same address.